The US represents a key market within North America, supported by expanding oncology drug pipelines, advanced clinical research, and increasing adoption of personalized and targeted therapies for leukemia, lymphoma, and myeloma. Recent regulatory activity, including new approvals for multiple myeloma treatments, is further strengthening innovation and treatment options. The Blood Cancer Drugs...